Physician

Dante Pieramici, M.D.

According to 2025 Medicare claims, Dante Pieramici, M.D. (NPI: 1992804504) practices ophthalmology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is CALIFORNIA RETINA CONSULTANTS (NPI: 1386737617; TIN: 223697030) and primary practice location at 93103-4223. Pieramici is affiliated with the Aledade A3299 CA MSSP Enhanced (ACO ID: A3299), participating under the MSSP model.

Pieramici's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,676 traditional Medicare patients, billed 49,034 HCPCS/CPT codes, and received $4,149,552 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 784 prescription claims across 243 beneficiaries totaling $46,768 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). 2021 DME data shows 11 claims. Open Payments data shows 178 records totaling $2,781,148. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,844	24,184	$3,651,071
2016	1,839	23,797	$3,658,487
2017	1,810	23,852	$3,651,953
2018	1,794	24,746	$4,015,878
2019	1,849	26,224	$4,181,947
2020	1,625	20,212	$3,763,066
2021	1,803	21,439	$4,201,125
2022	1,696	26,645	$4,169,667
2023	1,560	44,377	$3,781,123
2024	1,676	49,034	$4,149,552

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	571	$59,292
2016	202	666	$72,276
2017	234	900	$92,088
2018	276	967	$105,630
2019	271	1,048	$100,110
2020	224	879	$95,378
2021	231	861	$80,582
2022	236	819	$66,817
2023	215	631	$57,960
2024	243	784	$46,768

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	28	$1,704
2018	N/R	13	$1,227
2019	N/R	13	$1,789
2020	N/R	14	$1,190
2021	N/R	11	$703
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
67028	Injection of drug into eye	495	1,887	$101
92014	Established patient complete exam of visual system	1,101	1,410	$94
92012	Established patient problem focused exam of visual system	480	819	$68
92134	Imaging of retina	1,289	2,889	$31
92250	Photography of the retina	692	868	$28

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Prednisolone Acetate	Prednisolone Acetate	188	6,848	$8,271
Lumigan	Bimatoprost	18	897	$6,232
Brimonidine Tartrate	Brimonidine Tartrate	28	1,199	$3,402
Atropine Sulfate	Atropine Sulfate	71	2,260	$3,048
Bromfenac Sodium	Bromfenac Sodium	24	502	$3,021

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	73	$36,904	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	105	$2,744,243	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dante Pieramici, M.D.?

Tedicare shows public-source Medicare data for Dante Pieramici, M.D. (NPI 1992804504), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dante Pieramici, M.D. have ACO affiliation data?

Dante Pieramici, M.D. is shown with ACO affiliation data for Aledade A3299 CA MSSP Enhanced (MSSP, ACO ID A3299).

What billing organization is linked to Dante Pieramici, M.D.?

Dante Pieramici, M.D. is linked to CALIFORNIA RETINA CONSULTANTS (billing NPI 1386737617) in the available physician profile data.

Does Dante Pieramici, M.D. have Open Payments data?

Dante Pieramici, M.D. has 178 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.